Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GU Cancers 2025 | Evaluating HER2 as a biomarker in urothelial carcinoma

Xinan Sheng • 10 Feb 2025
GU Cancers 2025
Bladder Cancer Genitourinary Cancer Urothelial Carcinoma Trastuzumab deruxtecan Trastuzumab emtansine
RC48-C014 RC48-C017

Xinan Sheng, MD, Peking University Cancer Hospital & Institute, Beijing, China, comments on the role of HER2 as a biomarker in urothelial carcinoma, highlighting that anti-HER2 treatments, such as trastuzumab emtansine and trastuzumab deruxtecan, have shown significant efficacy in patients with HER2-positive tumors. Promising results from various trials such as the RC48-C014 (NCT04264936) and RC48-C017 (NCT05297552) trials, including high pCR rates and one-year event-free survival rates. This interview took place at the ASCO GU Cancers Symposium 2025 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Xinan Sheng

Recent improvements in HER2-targeting ADCs for genitourinary cancers
3:34
Recent improvements in HER2-targeting ADCs for genitourinary cancers
Xinan Sheng • 10 Feb 2025
Advances in neoadjuvant strategies for muscle-invasive bladder cancer
5:03
Advances in neoadjuvant strategies for muscle-invasive bladder cancer
Xinan Sheng • 10 Feb 2025
RC48-C017: disitamab vedotin and toripalimab in HER2-expressing MIBC
5:48
RC48-C017: disitamab vedotin and toripalimab in HER2-expressing MIBC
Xinan Sheng • 10 Feb 2025

Related Videos

Current and emerging systemic strategies in biochemically relapsed prostate cancer
2:45
Current and emerging systemic strategies in biochemically relapsed prostate cancer
Ashwin Sachdeva • 16 May 2026
How has SABR improved radiotherapy practice in kidney cancer?
1:06
How has SABR improved radiotherapy practice in kidney cancer?
Shankar Siva • 16 May 2026
Which patients with kidney cancer may benefit from SABR treatment?
1:58
Which patients with kidney cancer may benefit from SABR treatment?
Shankar Siva • 16 May 2026
Management of brain metastasis in patients with poor-risk testicular cancer
1:03
Management of brain metastasis in patients with poor-risk testicular cancer
Darren Feldman • 30 May 2026
The content of VJOncology is intended for healthcare professionals